Question normal

Is it correct to think that after 1 year most patients de-escalated to anticoag monotherapy with only either dabigatran or warfarin? If so, does the bump in cumulative incidence of secondary endpoints between days 630 - 720 represent an observed difference between the two anticoag therapies, perhaps driven by an increase in MI incidence in the 110 dabigatran group?